Introduction
============

The term "emerging adulthood" has been coined to describe the period of life approximately between the ages of 18 and 30 years when an individual separates from parental care and assumes responsibility for his or her own choices.[@b1-ppa-10-371] Broadly speaking, this developmental period consists of two stages: an early phase (\~18--24 years) reflecting the first few years after high school and a later phase (\~25--30 years) with the adoption of more traditional adult roles.[@b1-ppa-10-371] At this time of life, an emerging adult with a special health-related need (eg, diabetes, cystic fibrosis, organ transplantation, or a previous cancer diagnosis) faces all of the upheaval that may be experienced by his or her peers, compounded by the added burden of the chronic medical condition. The young person must navigate the often-foreboding chasm between pediatric and adult health care systems and simultaneously master self-care behavior skills in the face of competing peer-group influences. While the increased risk of adverse health outcomes during this vulnerable transition period is well recognized, there is a paucity of evidence supporting any specific strategy directed at smoothing the process.[@b2-ppa-10-371]

Several approaches have been trialed in an attempt to address these challenges, directed at a system (eg, transition clinics), staff (eg, transition coordinator), or individual (eg, peer-mentoring) level.[@b3-ppa-10-371] However, the results of these approaches have been mixed.[@b2-ppa-10-371] A systematic review of interventions designed to improve transition identified ten studies, of which four were controlled clinical trials, with study arms comprising 30--153 patients. A variety of interventions were studied, including separate young adult clinics, joint pediatric/adult clinics, and disease-specific education. Outcomes examined were primarily disease-specific clinical outcomes (eg, difference in glycemic control). These interventions demonstrated mixed effectiveness, with two of these four trials demonstrating an improvement in glycemic control in young people with diabetes.[@b2-ppa-10-371]

One strategy to encourage positive health-related choices is the use of incentives: motivating rewards provided contingently on behavioral performance.[@b4-ppa-10-371] The provision of behavioral incentives attempts to bridge the gap between what we actually do (first-order desires) and what we would like to do (second-order desires).[@b5-ppa-10-371] Such an approach may be especially appealing to the transitioning population, where the obstacles of complex health care structures and competing societal demands are compounded by an intrinsic imbalance in the relative development of the limbic system (early) and prefrontal cortex (later) that favors immediate reward processing over long-term rational decision making.[@b6-ppa-10-371]

In such areas as addiction medicine, behavioral incentives have been employed and studied for decades. For example, in 2006 Prendergast et al conducted a meta-analysis of contingency-management (CM) interventions for treatment of substance abuse and identified 75 studies, demonstrating a positive effect size (*d*=0.42).[@b7-ppa-10-371] More recently, Cahill et al updated their systematic review of incentives for smoking cessation, identifying 21 studies examining such incentives as lottery tickets, cash payments, and vouchers, and found an odds ratio for quitting of 1.42 (95% confidence interval 1.19--1.69).[@b8-ppa-10-371]

However, whether the same strategies can be extrapolated to promote positive health-related behaviors that exceed the societal norm for the peer group (eg, adherence to long-term medical therapy) is uncertain. Similarly, the effectiveness of incentive strategies specifically within the emerging adult population is unclear. Accordingly, we set out to conduct a systematic review of the use of incentive strategies in young adults with chronic medical diseases.

Methods
=======

We followed the Preferred Reporting Items for Systematic review and Meta-Analysis guidelines.[@b9-ppa-10-371]

Eligibility criteria
--------------------

We included studies that investigated an incentive used to achieve a target behavior or outcome in a pediatric or emerging adult population with chronic medical conditions, including addictions. We included studies of experimental (randomized controlled trials, controlled clinical trials) and observational (case-control, cohort, cross-sectional) design. We adopted Michie et al's definition of an incentive as a motivating reward provided contingently on behavioral performance,[@b4-ppa-10-371] and included cash payments, vouchers, and lotteries with or without CM ([Table 1](#t1-ppa-10-371){ref-type="table"}). We defined the emerging adult population as individuals aged 18--30 years.[@b1-ppa-10-371] We defined chronic disease as a condition of long duration or frequent recurrence that met the following criteria: 1) an impairment of the normal functioning of some aspect of the body, 2) characteristic signs or symptoms, and 3) harm or morbidity.[@b10-ppa-10-371] We applied this definition to a compendium of pediatric conditions,[@b11-ppa-10-371] and from this we generated a list of chronic diseases. Substance-use disorders, such as smoking, were included, as they met the aforementioned criteria.[@b12-ppa-10-371] The American Psychiatric Association diagnostic criteria for substance-use disorders can be categorized into impaired control (resulting in recurrent use), tolerance and withdrawal, social impairment, and risky use.[@b13-ppa-10-371] We did not include obesity, as our initial search was conducted prior to this condition being considered a disease by the American Medical Association.[@b10-ppa-10-371] Studies were included regardless of design, duration of follow-up, or language of publication.

Information sources and literature search
-----------------------------------------

The Medline, CINAHL, Embase, PsycInfo, and Cochrane databases were searched from inception until June 2014. Reference lists of included studies and relevant reviews were also reviewed. Searches were performed with no year or language restrictions, and used combinations of the search terms "incentives", "rewards", "chronic disease", and "youth and child", as well as search terms for specific chronic diseases. Appropriate wildcards were used in the search in order to account for plurals and variations in spelling. The search strategy was drafted and conducted by an information specialist.

Study selection process
-----------------------

We created a study manual detailing criteria for study selection. After completing a calibration exercise, two team members independently screened each abstract for inclusion; conflicts were resolved by discussion or by a third team member. Following selection of abstracts, two team members independently reviewed each full-text article for inclusion; conflicts were similarly resolved.

Data items and data collection process
--------------------------------------

We created a study manual and a data abstraction sheet detailing data items to be collected, and a calibration exercise was conducted (data abstraction manual and sheet are available upon request). We then abstracted the following data: study characteristics (design, country, setting), target population (chronic disease, sex, age, number), behavior incentivized, incentive intervention (type, value, nature, behavioral technique), duration (run-in period, period with incentive, follow-up period), cointervention, and outcomes (disease-specific behavioral outcome, eg, adherence, avoidance, and attendance, and disease-specific clinical outcome eg, carbon monoxide levels). Each full-text article was abstracted independently by two team members; conflicts were resolved by discussion or by a third team member.

Risk-of-bias assessment
-----------------------

For each study type (randomized controlled trial, controlled clinical trial, cohort, case-control, and cross-sectional), we abstracted relevant study characteristics to assess the risk of bias. Specifically, we adapted the Cochrane Collaboration's tool for assessing risk of bias[@b20-ppa-10-371] to the study designs that we included.

Synthesis
---------

We reported our results by descriptively summarizing literature-search results, types of studies, study quality and risk of bias, characteristics of target population and behaviors incentivized, follow-up, incentive characteristics, and outcome results. Meta-analyses by intervention type or disease outcomes were not possible, because of the heterogeneity of the disease states.

Results
=======

Literature search
-----------------

Medline, Embase, PsycInfo, CINAHL, and the Cochrane Central Register of Controlled Trials were searched on June 12--13, 2013 and retrieved 3,401, 3,288, 1,329, 3,414, and 169 studies, respectively. An update on the search was done on May 16, 2014, retrieving 352, 538, 180, 129, and 37 studies, respectively. A total of 29 full-text articles fulfilled the eligibility criteria. Three of the 29 articles were companion reports[@b21-ppa-10-371]--[@b23-ppa-10-371] of two primary publications.[@b15-ppa-10-371],[@b16-ppa-10-371] We report on the 26 primary publications ([Figure 1](#f1-ppa-10-371){ref-type="fig"}).

Types of studies
----------------

Fourteen articles reported the results of randomized controlled trials,[@b14-ppa-10-371],[@b16-ppa-10-371],[@b17-ppa-10-371],[@b19-ppa-10-371],[@b24-ppa-10-371]--[@b33-ppa-10-371] two reported the results of controlled clinical trials,[@b34-ppa-10-371],[@b35-ppa-10-371] one reported the results of a crossover clinical trial,[@b36-ppa-10-371] two reported the results of cohort studies,[@b6-ppa-10-371],[@b37-ppa-10-371] and seven reported the results of uncontrolled before--after studies.[@b15-ppa-10-371],[@b38-ppa-10-371]--[@b43-ppa-10-371] Eleven of the 26 trials described the effects of behavioral interventions when conducted along with cointerventions, including motivational enhancement therapy,[@b14-ppa-10-371],[@b16-ppa-10-371],[@b26-ppa-10-371],[@b28-ppa-10-371],[@b33-ppa-10-371] relaxation-control treatment,[@b14-ppa-10-371] cognitive behavioral therapy,[@b16-ppa-10-371],[@b31-ppa-10-371],[@b38-ppa-10-371] drug counseling,[@b16-ppa-10-371] multidisciplinary adherence support,[@b39-ppa-10-371] motivational interviewing,[@b39-ppa-10-371] and instructional materials or information.[@b32-ppa-10-371],[@b40-ppa-10-371],[@b41-ppa-10-371]

Methodological quality and risk-of-bias results
-----------------------------------------------

Twelve of the 14 randomized controlled trials had a high risk of bias on at least one of the seven criteria; all randomized controlled trials had an unclear risk of bias on at least one item. Of the two controlled trials and one crossover trial, none had a high risk of bias on any item, but did have unclear risk of bias on at least one of the four applicable items. Both cohort studies had a high risk of bias on selection of cohorts and matching and assessment of prognostic factors; additionally, one study had a high risk of bias due to cointerventions.

Characteristics of the target population and the behaviors incentivized
-----------------------------------------------------------------------

Among the 26 articles, 20 examined the effects of behavioral incentives on cigarette smoking or substance abuse, including alcohol (cigarette smoking, n=9; substance abuse, n=11), four studies explored behavioral incentives in the setting of HIV or sexual health (including herpes simplex type 2 or human papilloma virus \[HPV\]), and two articles studied individuals with other chronic medical conditions (cerebral palsy and congenital adrenal hyperplasia) ([Table 1](#t1-ppa-10-371){ref-type="table"}). One study tested the effectiveness of an integrated cognitive behavioral and CM intervention in young people with HIV with an alcohol- and/or cannabis-use disorder, where the primary focus was on substance abuse.[@b38-ppa-10-371] No studies were identified that specifically examined the effects of behavioral incentives among emerging adults with more commonly occurring chronic medical conditions (eg, childhood cancer, diabetes, asthma, epilepsy, or anemia).[@b44-ppa-10-371] Sixteen articles included participants from both the pediatric (\<18 years of age) and adult (≥18 years of age) populations, nine articles studied individuals over the age of 18 years only, and one article studied university students[@b32-ppa-10-371] ([Table 1](#t1-ppa-10-371){ref-type="table"}). The median number of study participants was 64, with eight participants in the smallest study[@b36-ppa-10-371] and 3,796 participants in the largest study.[@b19-ppa-10-371]

Types of incentive
------------------

The intervention types are summarized in [Table 1](#t1-ppa-10-371){ref-type="table"}. Eleven studies provided the incentive in the form of cash, six studies offered incentives in the form of vouchers, and nine articles described the use of a lottery scheme.

### Cash payments

The value of the incentives in the eleven trials that offered cash payments varied substantially. The median total value for a cash-payment financial incentive was \$120. The lowest value was \$14.40, for a study of adolescents with congenital adrenal hyperplasia (or healthy controls) where participants could "win" up to \$4.80 in a reward-based antisaccade task (whereby one inhibits a reflexive eye movement).[@b35-ppa-10-371] The highest total cash incentive that could be earned was \$523.50 over 3 weeks in a trial of smoking cessation.[@b14-ppa-10-371]

### Vouchers

Two studies that employed vouchers were from the same group of investigators, examining the use of CM and motivation/skill-building therapy among young adults with marijuana dependence.[@b16-ppa-10-371],[@b33-ppa-10-371] In the primary study, participants assigned to CM received "vouchers redeemable for goods and services purchased by study staff".[@b16-ppa-10-371] Attendance at treatment sessions was rewarded with an initial voucher worth \$25, increasing in \$5 increments for each consecutive session attended.[@b16-ppa-10-371] Participants also received \$50 for the first marijuana-free urine specimen, with increments of \$5 for each subsequent specimen received that was negative for marijuana.[@b16-ppa-10-371] The maximum value of vouchers that could be obtained was \$880.

One study specifically employed an incentive scheme to improve medication adherence in the transitioning population.[@b39-ppa-10-371] This article examined the effect of an incentive strategy on viral load in eleven patients with perinatally acquired HIV. Participants received gift vouchers of a value of £25 or £50 contingently on both fall in viral load and attendance for motivational interviewing.[@b39-ppa-10-371]

### Lottery

Lottery incentives fell into two broad categories. Five of the studies employed an incentive strategy where participants could draw from a prize bowl if they had achieved a contingent behavior.[@b17-ppa-10-371],[@b26-ppa-10-371],[@b28-ppa-10-371],[@b37-ppa-10-371],[@b38-ppa-10-371] As an example, in a study by Killeen et al, participants with primary marijuana-use disorder randomized to CM earned chances to draw from a prize bowl for provision of a negative urine drug screen in an escalating manner (number of chances increased by one per week), with a reset to zero for a positive test or an unexcused absence.[@b17-ppa-10-371] Prize bowl-chits could be exchanged for prizes, such as phone cards, video games, iPods, iTunes vouchers, or skateboards.[@b17-ppa-10-371]

The second type of lottery approach that was employed was a "quit and win" scheme utilized by two studies of smoking cessation.[@b40-ppa-10-371],[@b42-ppa-10-371] In these studies, all participants who had successfully quit smoking were eligible for a prize draw. Among the other two studies that offered a lottery scheme, both involved education on alcohol awareness and offered either a reward for successfully completing a quiz or entry into a raffle for maintaining a blood-alcohol content below a set target.[@b32-ppa-10-371],[@b41-ppa-10-371]

### With or without contingency management

A total of 25 of the 26 studies offered an incentive that was contingent on behavior. Only one study reported noncontingent incentives. This was a study of HPV-vaccine uptake in young women, where vouchers were provided to enable participants to receive all three doses of the HPV vaccine at no cost.[@b15-ppa-10-371] Thirteen studies described an escalation and reset strategy for the incentive,[@b14-ppa-10-371],[@b16-ppa-10-371],[@b17-ppa-10-371],[@b24-ppa-10-371],[@b26-ppa-10-371],[@b28-ppa-10-371],[@b29-ppa-10-371],[@b31-ppa-10-371]--[@b34-ppa-10-371],[@b36-ppa-10-371],[@b38-ppa-10-371] one study reported a reset scheme only,[@b37-ppa-10-371] and 12 studies incorporated neither an escalating strategy nor a reset.[@b6-ppa-10-371],[@b15-ppa-10-371],[@b19-ppa-10-371],[@b25-ppa-10-371],[@b27-ppa-10-371],[@b30-ppa-10-371],[@b35-ppa-10-371],[@b39-ppa-10-371]--[@b43-ppa-10-371] One article reported the use of a disincentive where participants could receive a "payment reduction" from their study compensation for decreased ability to complete four cognitive/psychomotor tasks following a 3-hour ad libitum drinking period.[@b27-ppa-10-371]

Studies reporting positive impact
---------------------------------

A total of 24 of the 26 studies reported a positive effect of the incentive strategy on either the primary or secondary outcome. Seventeen of these studies reported the effect as a statistically significant change (*P*\<0.05 or confidence interval that did not span unity). Two reported no benefit of the intervention.[@b17-ppa-10-371],[@b29-ppa-10-371] The outcomes and effect sizes for each intervention varied according to disease type.

All of the nine studies of smoking cessation sought objective evidence of abstinence as a primary outcome.[@b14-ppa-10-371],[@b24-ppa-10-371],[@b29-ppa-10-371]--[@b31-ppa-10-371],[@b36-ppa-10-371],[@b40-ppa-10-371],[@b42-ppa-10-371],[@b43-ppa-10-371] However, the effect size differed substantially between studies. For instance in an article by An et al, 7-day abstinence rates among college smokers were 100 of 360 (38.5%) in the control group and 152 of 257 (59.1%) in the group assigned to a web-based intervention (adjusted odds ratio 2.43, 95% confidence interval 1.70--3.48).[@b30-ppa-10-371] By way of contrast, in a study by Tevyaw et al of non-treatment-seeking daily smokers, only three of 49 (6.1%) participants receiving CM had verified 7-day point-prevalence abstinence vs 0 of 43 (0%) in the control group, with no significant differences according to treatment allocation.[@b14-ppa-10-371] Among the studies that evaluated incentive strategies for substance abuse, the primary outcome that was assessed reflected the heterogeneity of the study participants. As with smoking cessation, six studies sought evidence of abstinence, commonly in the form of a negative urine drug screen.[@b16-ppa-10-371],[@b17-ppa-10-371],[@b26-ppa-10-371],[@b33-ppa-10-371],[@b37-ppa-10-371],[@b38-ppa-10-371] Other outcomes that were assessed included vaccine-uptake rates,[@b25-ppa-10-371] number of alcoholic beverages consumed,[@b27-ppa-10-371] exercise frequency,[@b28-ppa-10-371] demonstration of knowledge gained,[@b41-ppa-10-371] blood-alcohol concentration,[@b32-ppa-10-371] and session attendance.[@b16-ppa-10-371],[@b33-ppa-10-371],[@b38-ppa-10-371] The outcomes assessed in the studies of emerging adults with cerebral palsy or congenital adrenal hyperplasia were disease- and intervention-specific (completion of frontal forearm flexor electromyography training and antisaccade accuracy).[@b34-ppa-10-371],[@b35-ppa-10-371]

Studies reporting no impact
---------------------------

One randomized controlled trial reported no change in either primary or secondary outcomes in cigarette smokers at 2-week follow-up.[@b29-ppa-10-371] However, this was a pilot in nature, consisting of 19 participants; a subsequent trial of 110 participants by the same authors reported a reduction in CO levels and greater abstinence during the CM intervention with 6 months' follow-up.[@b14-ppa-10-371] A separate randomized controlled trial examined the effects of a community-based CM strategy in 31 adolescents with primary marijuana-use disorder, and found that the intervention had no effect on the percentage of negative urine drug screens, sustained negative urine drug screens, or retention in treatment.[@b17-ppa-10-371] In a third randomized controlled trial, various behavior-modification strategies were assessed in combination with bupropion SR among 134 adolescent cigarette smokers, with pooled effects indicating that CM treatment was only marginally (and insignificantly) superior to non-CM treatment.[@b24-ppa-10-371]

Study reporting negative impact
-------------------------------

One of the articles reported negative outcomes. In this report, Corby et al described the effectiveness of CM in a cohort of eight adolescent cigarette smokers, interpreting that increasing negative mood with smoking cessation was indicative of nicotine-withdrawal syndrome.[@b36-ppa-10-371]

Follow-up
---------

Thirteen of the 26 studies did not report a follow-up of the participants after the incentive period was terminated ([Table 2](#t2-ppa-10-371){ref-type="table"}). Among the 13 that did, the median duration of follow-up was 2.5 months, with the shortest study following participants up for 1--3 days[@b27-ppa-10-371] and the longest following participants up for 12 months.[@b39-ppa-10-371] All but two of these 13 studies reported positive outcomes; these two studies reported follow-ups of 2 weeks[@b29-ppa-10-371] and 3 months.[@b17-ppa-10-371]

The article reporting a 12-month follow-up was the pilot study of incentives in individuals with perinatally acquired HIV. Three studies reported follow-up at 6 months after the study intervention. One of these examined the effectiveness of CM in young people with marijuana dependence, and found no difference between intervention strategies in the proportion of participants reporting no marijuana use in the 28 days prior to the 6-month follow-up.[@b16-ppa-10-371] In other studies with a 6-month follow-up, the "quit and win" study by Rooney et al failed to find a reduction in cigarette smoking at 6 months,[@b42-ppa-10-371] and rates of confirmed abstinence from cigarette smoking at 6 months were only 3.8% in a study by Tevyaw et al, with no difference according to treatment strategy.[@b14-ppa-10-371]

Discussion
==========

Despite widespread acknowledgment of the unique challenges that emerging adults with chronic medical diseases face, there have been relatively few studies evaluating interventions aimed at easing the transition to adulthood, and fewer still that have demonstrated benefit. Cognizant of this need, we sought to determine whether literature evidence exists that behavioral incentives may be of utility in this population. By way of systematic review, we found that behavioral incentive strategies in the young adult population have been almost exclusively employed in the discouragement of the continued practice of unhealthy behaviors, such as cigarette smoking and the abuse of alcohol or marijuana. In contrast, the use of incentives to encourage the adoption of positive self-care behaviors in young people with chronic medical conditions has been mostly overlooked. Few of the studies that did examine behavioral incentives in young adults had a low risk of bias, and few demonstrated sustained effects on long-term follow-up. Recognizing that emerging adults with chronic medical diseases face unique and distinct challenges, whether incentive strategies may have a utility in this population remains to be defined.

Illustrative of the dearth of trials evaluating interventions in young adults, in 2011 a systematic review evaluating any interventions facilitating health-related transitions in this population identified a total of only ten studies, eight of which were in young people with diabetes.[@b2-ppa-10-371] Even in the case of diabetes, however, the majority of guideline recommendations for emerging adults are based upon expert consensus or clinical experience, and not upon randomized controlled trial evidence or meta-analyses.[@b45-ppa-10-371] In our review, which was conducted up to May 2014, we found no studies that had employed incentive strategies specifically in the transitioning population with diabetes. Indeed, the only study we were able to identify that sought to evaluate the use of incentives to improve medication adherence and clinic attendance was a small study of eleven individuals with perinatally acquired HIV.

In contrast to studies of young adults with chronic medical diseases, such as diabetes or HIV, we identified 20 articles reporting the effects of behavioral incentives in promoting smoking cessation or avoidance of recreational drugs or alcohol. Whereas almost all the articles we identified described a beneficial effect of the incentive strategy, fewer reported a statistically significant change, the effect sizes were very variable, and were commonly either not assessed or sustained on long-term follow-up. Lack of follow-up and durability of the effect on follow-up are common criticisms of studies of financial incentives.[@b46-ppa-10-371]

One potential negative outcome of incentive strategies in the medium to long term is the risk of "crowding out" the desired behavior, ie, a reduction in the time spent on the task, either when the reward is removed or while the incentive is still in place. Evidence supporting this concern exists in both the psychological and economic literature.[@b47-ppa-10-371] For example, in cognitive evaluation theory there are circumstances where intrinsic motivation to complete an interesting task is high, and the provision of an incentive can diminish time spent on the task once the incentive is removed.[@b47-ppa-10-371] In behavioral economics, "motivation crowding out" has a broader definition, referring to any effect that is the opposite of the desired behavior. This opposite effect often arises when there is a conflict of interest between the incentivizing and incentivized parties.[@b47-ppa-10-371] There are, however, several characteristics of health behaviors that suggest that the effects of crowding out may be different or unapparent when incentivizing health choices. For example, in most cases the intrinsic motivation to adopt the desired health behavior is generally low, and an interpersonal conflict is often unapparent.[@b47-ppa-10-371] Furthermore, many detrimental health-related behaviors can be perceived as problems of self-control, and an incentive may provide a temporal bridge between immediate benefit and long-term health benefit. At the present time at least, there is an absence of evidence in the literature supporting a prominent effect of crowding out phenomena undermining the effects of incentives for health-related behaviors.[@b47-ppa-10-371]

In most of the articles identified through our systematic review, interventions were designed to assist an individual in "breaking bad habits". In this setting, behavioral incentives usually take the form of conventional CM approaches, where a reward is provided contingently on the objective demonstration of cessation of the behavior and withdrawn when the behavior is readopted. From a societal perspective, incentive strategies under these circumstances have come under criticism for unfairly rewarding "bad behavior",[@b5-ppa-10-371] likely contributing to the perceived relative unacceptability of financial incentives compared to other interventions of theoretically equal efficacy.[@b48-ppa-10-371] In contrast, it is possible that the use of incentives to encourage "good behaviors" (eg, self-monitoring of blood glucose in people with diabetes) may be deemed more acceptable.[@b48-ppa-10-371] Similarly, the response to the incentive under these circumstances may be distinct, and cannot necessarily be predicted from that in the cigarette-smoking/substance-abuse setting. Unfortunately, we found few studies that addressed the use of incentives to promote the adoption of healthy behavior choices that extended beyond those expected of the population in general. In contrast, a systematic review of incentives in the adult population identified 34 relevant trials, with 19 focused on smoking cessation and 15 on healthier eating or physical activity; it found that incentives could change health-related behavior, but effects were short-lived.[@b49-ppa-10-371] That being said, it is noteworthy that a recent article published online in 2015 found that providing monetary reinforcers (\$0.10/test) increased the frequency of blood-glucose testing in ten adolescents over a 12-week period.[@b50-ppa-10-371] Whether these positive behaviors can be sustained and be replicated in a larger patient cohort remains to be seen.

In considering the reasons affecting the "acceptability" of financial incentives in the health care setting, it has been recognized that the transfer of cash or an equivalent between health care provider and receiver may be viewed as breaching a cultural norm.[@b48-ppa-10-371],[@b51-ppa-10-371] Therefore, provision of the incentive in the form of a voucher rather than cash may be more acceptable.[@b48-ppa-10-371] In the present review, approximately even numbers of studies offered the reward as cash and as vouchers. A competitive or chance element to reward provision was also commonly employed. In terms of the value of the rewards, a previous study of prize reinforcement in cocaine users noted superior outcomes with an expected maximum reinforcement of \$240 compared to \$80,[@b52-ppa-10-371] whereas the median cash payment in the present review was \$120, with only three studies exceeding \$240.[@b14-ppa-10-371],[@b24-ppa-10-371],[@b31-ppa-10-371] Conflicting meta-analyses have described both a positive and negative relationship between the value of the incentive and its efficacy.[@b46-ppa-10-371]

Our study had limitations. With the desire to examine the use of incentive strategies in individuals with chronic medical conditions, we elected not to study their role in weight management. Our initial search was conducted 1 week before obesity was declared a disease by the American Medical Association,[@b10-ppa-10-371] and even now such a designation remains controversial.[@b53-ppa-10-371] A recent systematic review pointed toward the positive association between incentives and dietary behavior change in the short term.[@b54-ppa-10-371] However, a separate meta-analysis of weight-loss trials with a follow-up of at least 1 year or more showed no benefit of incentives.[@b55-ppa-10-371] Interestingly, another systematic review and meta-analysis set out to examine the effects of incentive strategies specifically on behavior in "free-living 'healthy' adults" by focusing on the nonclinical adult population,[@b46-ppa-10-371] identifying 17 papers (reporting on 16 studies), with no overlap with the present review.[@b46-ppa-10-371] In that review, there were ten studies of smoking cessation, five of attendance for vaccination or screening, and one of physical activity, with meta-analyses revealing a positive effect of incentives over both the short (≤6 months) and longer (\>6 months) term and with some indication of a waning of effect size over time. In the present review, we focused on identifying the types of incentive strategies employed in the emerging adult population and the medical conditions in which they had been assessed, rather than outcomes, appreciating at the outset that: 1) a disparate set of outcome measures would preclude meta-analysis, and 2) even if a strategy had demonstrated benefit during the period of study, its durability on follow-up may not have been demonstrated or even studied.

Conclusion
==========

In summary, although health care providers readily recognize the difficulties emerging adults with chronic medical conditions face, few studies have been undertaken that address these challenges. Behavioral incentives have been employed with short-term benefit in other patient groups. In the emerging adult population, these strategies have been most extensively studied in the context of the discouragement of cigarette smoking or marijuana use. The assimilation of study characteristics herein described may inform ongoing and future clinical trials to determine whether such an approach may play any role in the medical management of emerging adults with chronic medical conditions.
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###### 

Types of incentives and their definition

  Incentive type                                      Definition                                                                                                                                   Example
  --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cash payment                                        Direct payments of money in the form of cash                                                                                                 Cash given to participants to attend a smoking-cessation session[@b14-ppa-10-371]
  Voucher                                             A form or check indicating a credit against future purchases or expenditures                                                                 Voucher for HPV-vaccine doses,[@b15-ppa-10-371] goods purchased by study staff[@b16-ppa-10-371]
  Lottery                                             Drawing of lots in which prizes are distributed to the winners among persons buying a chance                                                 Participants receive chits to draw for items in a prize bowl, such as phone cards, iTunes vouchers, skateboards, jewelry, etc[@b17-ppa-10-371]
  Deposit contract                                    Participants put their own money at risk, which can be recouped if designated contingencies are met, but lost if target outcome is not met   Participant contributes 0--\$3 per day of their own funds to a deposit contract each day; if goal met, participant accumulates a reward equal to the daily deposit, plus 1:1 match from the investigator; if goal not met, deposit contract money is forfeited[@b18-ppa-10-371]
  **The incentive can be further characterized by**                                                                                                                                                
  Contingency management                              Receipt of the incentive is contingent on achieving an outcome                                                                               Payment received if girl attended school 80% of days[@b19-ppa-10-371]
  Escalating schedule                                 With each consecutive desired outcome, the incentive value is increased                                                                      With each negative carbon monoxide breath sample, incentive value is increased[@b14-ppa-10-371]
   Reset of escalating schedule                       Escalating schedule of incentive can be reset if desired outcome not met                                                                     Incentive value reset to lowest value if positive carbon monoxide breath sample[@b14-ppa-10-371]

**Abbreviation:** HPV, human papilloma virus.

###### 

Study characteristics

  Study                                      Condition             Participants (n)   Age range (years)     Intervention            Primary effective      Secondary effective   Negative outcome   Follow-up duration   Sustained at follow-up
  ------------------------------------------ --------------------- ------------------ --------------------- ----------------------- ---------------------- --------------------- ------------------ -------------------- ------------------------------------------------
  **Randomized controlled trials**                                                                                                                                                                                       
  Baird et al[@b19-ppa-10-371]               HIV/HSV-2             3,796              13--22                Cash transfer           Yes                    Yes                   No                 0 month              NA
  Glindemann et al[@b32-ppa-10-371]          SA                    702                University students   Lottery                 Yes                    No change             No                 0 month              NA
  Tevyaw et al[@b14-ppa-10-371]              Smoking               110                18--24                Cash payment            Yes                    Yes                   No                 6 months             No
  Gray et al[@b24-ppa-10-371]                Smoking               134                12--21                Cash payment            Yes (with bupropion)   NA                    No                 1.5 months           No
  Killeen et al[@b17-ppa-10-371]             SA                    31                 12--18                Lottery                 No change              No                    No                 3 months             Yes for group by time interaction for cravings
  Campbell et al[@b25-ppa-10-371]            SA, vaccine uptake    3,181              15--30                Cash payment            Yes                    No change             No                 0 month              NA
  Steele Seel[@b26-ppa-10-371]               SA                    14                 16--25                Lottery                 Yes                    Yes                   No                 2 months             Yes
  Leeman et al[@b27-ppa-10-371]              SA                    39                 21--25                Cash payment            Yes                    Yes                   No                 1--3 days            NA[\*](#tfn2-ppa-10-371){ref-type="table-fn"}
  Weinstock et al[@b28-ppa-10-371]           SA                    31                 18--27                Lottery                 Yes                    Yes                   No                 0 month              NA
  Tevyaw et al[@b29-ppa-10-371]              Smoking               19                 14--18                Cash payment            No change              No change             No                 0.5 month            No change
  An et al[@b30-ppa-10-371]                  Smoking               517                18--24                Voucher                 Yes                    Yes                   No                 6 months             NA
  Krishnan-Sarin et al[@b31-ppa-10-371]      Smoking               28                 14--18                Cash payment            Yes                    Yes                   No                 0 month              NA
  Carroll et al[@b16-ppa-10-371]             SA                    136                18--24                Voucher                 Yes                    NA                    No                 6 months             Yes
  Sinha et al[@b33-ppa-10-371]               SA                    65                 18--25                Voucher                 Yes                    Yes                   No                 1 month              Yes
  **Controlled clinical trials**                                                                                                                                                                                         
  Finley et al[@b34-ppa-10-371]              Cerebral palsy        15                 4--22                 Cash payment            Yes                    NA                    No                 0 month              NA
  Mueller et al[@b35-ppa-10-371]             CAH                   63                 15--16                Cash payment            Yes                    NA                    No                 0 month              NA
  **Crossover clinical trials**                                                                                                                                                                                          
  Corby et al[@b36-ppa-10-371]               Smoking               8                  15--19                Cash payment            Yes                    NA                    Yes                0.5 month            No
  **Cohort studies**                                                                                                                                                                                                     
  Black et al[@b6-ppa-10-371]                HIV/HSV-2             802                12--22                Voucher                 Yes                    Yes                   No                 0 month              NA
  Lott and Jencius[@b37-ppa-10-371]          SA                    336                12--18                Lottery                 Yes                    Yes                   No                 0 month              NA
  **Uncontrolled before--after studies**                                                                                                                                                                                 
  Foster et al[@b39-ppa-10-371]              HIV                   11                 16--23                Voucher                 Yes                    NA                    No                 12 months            Yes
  Casey et al[@b15-ppa-10-371]               HPV                   495                18--26                Voucher                 Yes                    NA                    No                 0 month              NA
  Esposito-Smythers et al[@b38-ppa-10-371]   SA, sexual behavior   17                 18--24                Lottery                 Yes                    Yes                   No                 3 months             Yes
  Hanewinkel and Wiborg[@b40-ppa-10-371]     Smoking               1,265              14--25                Lottery, quit and win   Yes                    NA                    No                 0 month              NA
  Rofael[@b41-ppa-10-371]                    SA                    14                 14--20                Lottery                 Yes                    NA                    No                 0 month              NA
  Rooney et al[@b42-ppa-10-371]              Smoking               152                18--24                Lottery, quit and win   Yes                    NA                    No                 6 months             No
  Weissman et al[@b43-ppa-10-371]            Smoking               11                 13--18                Cash payment            Yes                    NA                    No                 2--3 months          Yes

**Note:**

NA because the follow-up was to administer disincentive and not to see sustained effects of the incentive.

**Abbreviations:** SA, substance abuse; NA, not applicable; CAH, congenital adrenal hyperplasia; HPV, human papilloma virus; HSV, herpes simplex virus.
